ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Bosutinib (or SKI-606) is an oral once-daily dual Src/ABL inhibitor approved by FDA for the treatment of adult patients with CP, AP or BP Ph+CML, resistant or intolerant to imatinib or second-generation TKIs.